Hemostemix’s patented ACP-01 and NCP-01 autologous cell therapies demonstrate potential to extend brain–computer interface functional lifespan beyond one year by modulating inflammatory responses, stimulating angiogenesis through VEGF and IL-8 signaling, and enhancing synaptogenesis and neural plasticity. This approach aims to improve implant integration and signal fidelity for advanced neuroprosthetic applications.

Key points

• ACP-01 secretes CXCL8, VEGF, and angiogenin to recruit NK cells and CD34+ progenitors, driving angiogenesis and inflammation suppression at BCI sites.
• NCP-01 utilizes CXCR4-mediated homing to implant regions, differentiates into neuronal and glial cells, and supports synaptogenesis for improved signal integration.
• Combined intracerebrospinal delivery of ACP-01 and NCP-01 addresses inflammatory scarring and neural loss, potentially extending BCI functional lifespan and maintaining signal fidelity.

Why it matters: This dual-cell approach could transform neuroprosthetic interfaces by significantly extending implant longevity, enhancing signal quality, and improving patient outcomes.

Klotho Neurosciences, Inc. is expanding its development focus beyond neurodegenerative disorders to include complementary longevity and anti-aging technologies. The company is evaluating acquisitions and assembling a multidisciplinary team to target key biomolecules—such as alpha- and beta-Klotho, FOXO3, and anti-myostatin—to develop interventions aimed at preserving cognitive function, muscular strength, bone health, and overall organ health to delay age-related diseases.

Key points

• Deployment of proprietary KLTO-101 and KLTO-202 gene therapy candidates targeting neurodegenerative pathways, now advancing into broader anti-aging applications.
• Assembly of a multidisciplinary scientific team to evaluate biomolecular targets—including alpha-Klotho, beta-Klotho isoforms, FOXO3 transcription factors, and anti-myostatin—for longevity interventions.
• Strategic acquisition approach to integrate complementary technologies aimed at preserving cognitive function, muscle mass, bone density, and organ health across multiple age-related diseases.

Why it matters: This expansion leverages Klotho’s multimodal aging pathways to pioneer next-generation longevity therapeutics with the potential to delay multiple age-related diseases.

Klotho Neurosciences has demonstrated that their adeno-associated virus (AAV9) platform delivers the secreted form of the Klotho protein (s-KL) to increase circulating levels, resulting in a 20% extension of healthy lifespan in mice. Building on foundational work linking Klotho to aging, this approach targets multiple age-associated pathologies—including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis—offering a unified therapeutic strategy.

Key points

• AAV9-mediated delivery of secreted Klotho (s-KL) increases mouse lifespan by 20%.
• Overexpression of full-length Klotho gene extends murine lifespan by 30–40%.
• s-KL therapy mitigates cognitive decline, neuroinflammation, sarcopenia, and osteoporosis.

Why it matters: Demonstrating a single protein-based therapy that extends healthy lifespan and ameliorates multiple age-related diseases marks a paradigm shift in anti-aging therapeutics.